WO2022055243A1 - 인플루엔자 a 바이러스에 대한 항바이러스용 조성물 - Google Patents
인플루엔자 a 바이러스에 대한 항바이러스용 조성물 Download PDFInfo
- Publication number
- WO2022055243A1 WO2022055243A1 PCT/KR2021/012191 KR2021012191W WO2022055243A1 WO 2022055243 A1 WO2022055243 A1 WO 2022055243A1 KR 2021012191 W KR2021012191 W KR 2021012191W WO 2022055243 A1 WO2022055243 A1 WO 2022055243A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- influenza
- subtype
- seq
- scfv
- Prior art date
Links
- 241000712431 Influenza A virus Species 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 57
- 239000012634 fragment Substances 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 6
- 206010022000 influenza Diseases 0.000 claims description 34
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 229960003752 oseltamivir Drugs 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 5
- 241000197306 H1N1 subtype Species 0.000 claims description 4
- 241000252870 H3N2 subtype Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 64
- 101710154606 Hemagglutinin Proteins 0.000 description 57
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 57
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 57
- 101710176177 Protein A56 Proteins 0.000 description 57
- 239000000185 hemagglutinin Substances 0.000 description 49
- 210000004072 lung Anatomy 0.000 description 31
- 241000700605 Viruses Species 0.000 description 24
- 102000011931 Nucleoproteins Human genes 0.000 description 21
- 108010061100 Nucleoproteins Proteins 0.000 description 21
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 20
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 102000005348 Neuraminidase Human genes 0.000 description 19
- 108010006232 Neuraminidase Proteins 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 17
- 108020000999 Viral RNA Proteins 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 14
- 208000037797 influenza A Diseases 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000009385 viral infection Effects 0.000 description 12
- 241000712461 unidentified influenza virus Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 108090000467 Interferon-beta Proteins 0.000 description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940061367 tamiflu Drugs 0.000 description 4
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012120 mounting media Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000012163 TRI reagent Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Definitions
- the present invention relates to a composition for antiviral against influenza A virus.
- Influenza commonly known as 'the flu', is a contagious febrile respiratory disease caused by an influenza virus. Influenza A and B viruses spread to people and cause seasonal flu outbreaks each year. According to the World Health Organization (WHO), influenza virus transmission causes about 3 to 5 million severe cases and about 290,000 to 650,000 deaths. The WHO recommends annual influenza vaccination for high-risk groups, and vaccines are generally effective against three to four types of influenza. However, because viruses evolve rapidly, a vaccine made in one year may not be useful the following year. The genomes of influenza A and B viruses can be mutated in two ways: antigenic drift and antigenic shift, and thus existing vaccines or antiviral agents show low antiviral efficacy against viruses. Therefore, even if a mutation occurs in the genome of the influenza virus, there is a need to develop a material exhibiting excellent antiviral efficacy.
- WHO World Health Organization
- An object of the present invention is to provide a composition for antiviral against influenza A virus.
- An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of influenza A virus infection disease.
- An object of the present invention is to provide a food composition for preventing or improving influenza A virus infection disease.
- Heavy chain CDR1 represented by SEQ ID NO: 1 (VH CDR1), VH CDR2 represented by SEQ ID NO: 2, and VH CDR3 represented by SEQ ID NO: 3, light chain CDR1 represented by SEQ ID NO: 4 (VL CDR1), SEQ ID NO: 5
- An antiviral composition for influenza A virus comprising an antibody or fragment thereof comprising the VL CDR2 represented by and the VL CDR3 represented by SEQ ID NO: 6.
- influenza A virus is influenza A virus H1 subtype, influenza A virus H2 subtype, influenza A virus H5 subtype and influenza A virus H6 subtype, influenza A virus H3 subtype, influenza A virus
- An antiviral composition which is at least one selected from the group consisting of H4 subtype, influenza A virus H14 subtype, and variants thereof.
- influenza A virus is at least one selected from the group consisting of influenza A virus N1 subtype, influenza A virus N2 subtype, and variants thereof.
- influenza A virus is at least one of H1N1 subtype, H3N2 subtype, and variants thereof.
- influenza A virus is an oseltamivir-resistant influenza A virus.
- a pharmaceutical composition for preventing or treating influenza A virus infection disease comprising the composition of any one of items 1 to 8 above.
- a food composition for preventing or improving influenza A virus infection disease comprising the composition of any one of items 1 to 8 above.
- the antibody or fragment thereof contained in the antiviral composition of the present invention may penetrate into virus-infected cells, bind to influenza A virus RNA and degrade it.
- Antiviral composition of the present invention exhibits an excellent antiviral effect on influenza A virus by specifically binding to influenza A virus and hydrolyzing it, and influenza A It may exhibit the effect of preventing, treating, or ameliorating a viral infection disease.
- the antiviral composition of the present invention may exhibit excellent antiviral efficacy against various subtypes of influenza A virus or its variants.
- the antiviral composition of the present invention may exhibit excellent antiviral efficacy against oseltamivir-resistant influenza A virus.
- FIG 1 shows the sequence of an antibody or fragment thereof according to an embodiment.
- FIG. 2 shows a partial structure of a recombinant vector for the production of an antibody fragment according to an embodiment.
- Figure 3 shows the intracellular penetration activity of the antibody fragment according to an embodiment.
- FIG 4 shows the viral RNA (NA and NP) hydrolytic activity of the antibody fragment according to an embodiment.
- 5 shows the results of confirming the intracellular toxicity of the antibody fragment according to an embodiment through MTT analysis.
- FIG. 6 shows a schematic diagram and test results for testing the antiviral effect (cell viability) of 3D8 scFv pretreatment against influenza A virus strains (H1N1/PR8, H3N2/X-31 and H1N1/H275Y) (*P ⁇ 0.05 , **P ⁇ 0.01, ***P ⁇ 0.001).
- FIG. 7 shows a schematic diagram and test results for testing the antiviral effect (cell viability) of 3D8 scFv post-treatment against influenza A virus strains (H1N1/PR8, H3N2/X-31 and H1N1/H275Y) (*P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001).
- Figure 8 shows the results of the test results of the antiviral effect (viral RNA/protein expression level) of the 3D8 scFv pre/post-treatment on the H1N1/PR8 strain.
- Figure 9 shows the results of the antiviral effect (viral RNA/protein expression level) test results of the 3D8 scFv pre/post-treatment on the H3N2/X-31 strain.
- FIG. 11 shows the results of detection of viral protein HA in cells infected with influenza virus after 3D8 scFv was pre-treated (nucleus: DAPI (blue), 3D8 scFv: Alexa flour 488 (green), virus HA: TRITC (red)) .
- FIG. 12 shows the results of detecting viral protein HA after 3D8 scFv was post-treated in cells infected with influenza virus (nucleus: DAPI (blue), 3D8 scFv: Alexa flour 488 (green), virus HA: TRITC (red)) ).
- FIG. 13 shows a schematic diagram of the 3D8 scFv treatment and H1N1/H275Y infection protocol in mice for in vivo antiviral activity testing.
- 17 shows the average body weight of influenza virus-infected mice.
- FIG. 20 shows the results of qRT-PCR analysis of viral RNA (HA, NP) and IFN- ⁇ expression in influenza virus-infected mice.
- 21 shows the viral titer of influenza virus-infected mice through plaque assay.
- Figure 23 is a schematic diagram of a proposed model of the mechanism of action of an antibody fragment according to an embodiment.
- Figure 23 (A) shows the replication pathway of the influenza virus
- Figure 23 (B) shows the cell penetration mechanism of the antibody fragment according to an embodiment.
- Figure 23 (C) shows the hydrolysis mechanism of influenza A virus RNA by the antibody fragment according to an embodiment in the cytoplasm.
- HA hemagglutinin
- the present invention relates to a heavy chain CDR1 represented by SEQ ID NO: 1 (VH CDR1), a VH CDR2 represented by SEQ ID NO: 2, and a VH CDR3 represented by SEQ ID NO: 3, a light chain CDR1 represented by SEQ ID NO: 4 (VL CDR1), SEQ ID NO: It provides an antiviral composition for influenza A virus comprising an antibody or fragment thereof comprising the VL CDR2 represented by 5 and the VL CDR3 represented by SEQ ID NO: 6.
- complementarity determining region is a region involved in antigen recognition, and the specificity of the antibody to the antigen is determined as the sequence of this region changes.
- VH CDRs refer to the heavy chain complementarity determining regions present in the heavy chain variable region
- VL CDRs refer to the light chain complementarity determining regions present in the light chain variable regions.
- variable region refers to a region that shows sequence variation while performing a function of specifically binding to an antigen, and CDR1, CDR2 and CDR3 exist in the variable region.
- a framework region (FR) portion exists between the CDRs, which may serve to support the CDRs. Irrespective of the framework regions, CDRs may be important regions that allow an antibody or fragment thereof to exhibit a specific function.
- the antibody or fragment thereof may include a heavy chain variable region comprising a heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, a VH CDR2 represented by SEQ ID NO: 2, and a VH CDR3 represented by SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 (VL CDR1) represented by SEQ ID NO: 4, a VL CDR2 represented by SEQ ID NO: 5, and a VL CDR3 represented by SEQ ID NO: 6.
- the antibody or fragment thereof may include a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7. According to one embodiment, the antibody or fragment thereof may include a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 7.
- the antibody or fragment thereof may include a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. According to one embodiment, the antibody or fragment thereof may include a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 8.
- Fragments of antibodies are single chain antibodies, Fv, scFv, di-scFv, Fab, Fab', F(ab') 2 , Fd, LC, dAb, CDR, scFv-Fc, and the group consisting of diabodies It may be at least one selected from.
- the fragment of the antibody may comprise the amino acid sequence of SEQ ID NO: 9.
- the antibody fragment may be composed of the amino acid sequence of SEQ ID NO: 9.
- the antibody fragment may be an scFv consisting of the amino acid sequence of SEQ ID NO: 9.
- the antibody or fragment thereof may be a humanized antibody or fragment thereof; Or it may be a chimeric antibody or a fragment thereof.
- Humanized antibodies can be prepared by methods known in the art.
- the antibody fragment may be a humanized scFv comprising the CDR sequences of the scFv of SEQ ID NO: 9.
- the antibody or fragment thereof of the present invention can penetrate into the cytoplasm of a virus-infected host cell.
- the penetrating effect of the antibody or fragment thereof into the cytoplasm can be considered to be due to Caveolae mediated endocytosis.
- the antibody or fragment thereof of the present invention may specifically bind to a nucleic acid of influenza A virus. Specifically, the antibody or fragment thereof of the present invention may specifically bind to RNA of influenza A virus.
- the antibody or fragment thereof of the present invention has nuclease activity and can degrade RNA and DNA of viruses.
- the antibody or fragment thereof of the present invention can penetrate into the cytoplasm of a host infected with influenza A virus, and by removing naked viral RNA from the infected cells, it induces a decrease in the amount of viral gene replication and a decrease in the viral protein, and the efficacy of virus treatment can have
- Influenza A virus as a surface antigen may be divided into hemagglutinin (HA) subtype and neuraminidase (NA) subtype or variants thereof.
- HA hemagglutinin
- NA neuraminidase
- the mutant may be a mutant of an influenza A virus subtype, for example, a mutation in hemagglutinin and/or neuraminidase of the influenza A virus.
- the mutant is a mutant of the influenza A virus subtype, and may be one in which Oseltamivir (Tamiflu) resistance is exhibited due to a mutation in neuraminidase of the influenza A virus.
- the variant may be H1N1/H275Y.
- H1N1/H275Y is a protein mutation resulting from H1N1/pdm09.
- Tamiflu The mechanism of action of Tamiflu is to prevent the spread by inhibiting the spike protein of neuraminidase of H1N1.
- H1N1/H275Y where the amino acid mutation of H275Y of neuraminidase of H1N1 occurs, has very weak binding force between neuraminidase and Tamiflu, so Tamiflu is resistant. This appears.
- Hemagglutinin can play a role in recognizing the surface of the host cell and penetrating the inside of the cell. In addition, it can induce various inflammatory responses inside the cell and play a role in replicating itself.
- Influenza A virus may be of various types of subtypes defined by hemagglutinin or variants thereof.
- the subtypes defined by hemagglutinin are H1 subtype, H2 subtype, H3 subtype, H4 subtype, H5 subtype, H6 subtype, H7 subtype, H8 subtype, H9 subtype, H10 subtype , H11 subtype, H12 subtype, H13 subtype, H14 subtype, H15 subtype, and H16 subtype ( FIG. 24 ).
- Influenza A virus H1, H2 and H3 subtypes cause disease mainly in humans.
- Influenza A virus is a subtype comprising H1 hemagglutinin, a subtype comprising H2 hemagglutinin, a subtype comprising H3 hemagglutinin, a subtype comprising H4 hemagglutinin, and H5 hemagglutinin.
- the influenza A virus may be at least one of the remaining 15 subtypes except for the H1 subtype among 16 subtypes defined by hemagglutinin (HA).
- HA hemagglutinin
- an antibody or fragment thereof of the present invention may comprise influenza A virus H1 subtype, influenza A virus H2 subtype, influenza A virus H5 subtype and influenza A virus H6 subtype, influenza A virus H3 subtype, influenza A virus It may exhibit antiviral efficacy against at least one selected from the group consisting of H4 subtype, influenza A virus H14 subtype, and variants thereof.
- the antibody or fragment thereof of the present invention may exhibit antiviral efficacy against at least one selected from the group consisting of influenza A virus H1 subtype, influenza A virus H3 subtype, and variants thereof.
- influenza A virus may be a variety of subtypes and variants thereof defined by neuraminidase (NA).
- NA neuraminidase
- Neuraminidase is an enzyme that acts as a 'scissor' so that the virus that has proliferated in the host cell can break through the cell membrane, and can play a key role in the spread of the virus.
- influenza A virus is influenza A virus N1 subtype, N2 subtype, N3 subtype, N4 subtype, N5 subtype, N6 subtype, N7 subtype, N8 subtype, N9 subtype and variants thereof.
- the influenza A virus may be a subtype comprising N1 neuraminidase, a subtype comprising N2 neuraminidase, and variants thereof.
- the antibody or fragment thereof of the present invention may exhibit antiviral efficacy against at least one selected from the group consisting of influenza A virus N1 subtype, influenza A virus N2 subtype, and variants thereof.
- the antibody or fragment thereof of the present invention exhibits antiviral efficacy against at least one selected from the group consisting of H1N1 subtype, H3N2 subtype, and variants thereof.
- the antibody or fragment thereof of the present invention may exhibit antiviral efficacy against H1N1/PR8, H3N2/X-31, H1N1/H275Y virus strains.
- the present invention provides a pharmaceutical composition for preventing or treating influenza A virus infection disease comprising the antiviral composition described above.
- antiviral composition antibody or fragment thereof, and influenza A virus have been described above, so a detailed description thereof will be omitted.
- the present invention provides a pharmaceutical composition capable of treating influenza A virus infection disease comprising the above-described antiviral composition.
- prevention refers to any action that suppresses a disease caused by a virus or delays the onset of the disease.
- treatment refers to any action in which the symptoms of a disease caused by a virus are improved or beneficially changed.
- Influenza A virus may be a subtype defined by hemagglutinin (HA) or a variant thereof.
- the subtypes defined by hemagglutinin (HA) are H1 subtype, H2 subtype, H3 subtype, H4 subtype, H5 subtype, H6 subtype, H7 subtype, H8 subtype, H9 subtype type, H10 subtype, H11 subtype, H12 subtype, H13 subtype, H14 subtype, H15 subtype, and H16 subtype ( FIG. 24 ).
- the influenza A virus may be a variety of subtypes and variants thereof defined by neuraminidase (NA).
- NA neuraminidase
- influenza A virus is influenza A virus N1 subtype, N2 subtype, N3 subtype, N4 subtype, N5 subtype, N6 subtype, N7 subtype, N8 subtype, N9 subtype and variants thereof.
- NA neuraminidase
- influenza A virus may be at least one selected from the group consisting of H1N1 subtype, H3N2 subtype, and variants thereof.
- Influenza A virus infectious diseases include fever, vomiting, diarrhea, malaise, cough, dyspnea, pneumonia, headache, muscle pain, sputum, sore throat, flu, cold, pain/pressure in the chest, and dizziness. It may include, but is not limited thereto, if it is a disease caused by a viral infection.
- Influenza A virus infectious disease is not limited as long as it is a disease showing clinical symptoms of influenza A.
- the pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, drug therapy, and biological response modifiers for the prevention and treatment of diseases.
- the pharmaceutical composition may include an additional component effective against influenza A virus infection, and the additional component may be any component known to be effective against viral infection, including compounds, natural products, proteins, peptides, nucleic acids, and the like.
- the pharmaceutical composition may further include suitable carriers, excipients and diluents conventionally used in the preparation of the composition.
- Carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.
- the pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods, such formulations can be performed by a method commonly performed in the pharmaceutical field. In the case of formulation, it may be prepared by additionally using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose or lactose ( lactose), gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc., and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents, may be included.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
- a non-aqueous agent and suspending agent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used.
- a base of the suppository witepsol, macrogol, tween, cacao butter, laurin, glycerogelatin, and the like can be used.
- the present invention provides a food composition for the prevention or improvement of influenza A virus infection disease comprising the above-described antiviral composition.
- Antiviral compositions, antibodies or fragments thereof, influenza A virus and diseases have been described above, and thus detailed descriptions thereof will be omitted.
- the present invention provides a food composition that can improve influenza A virus infection disease comprising the antiviral composition described above.
- improvement refers to any action that reduces the symptoms of a disease caused by a virus.
- the food composition may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient included in the food composition may be suitably determined according to the purpose of its use (for prevention or improvement).
- the type of food composition is not particularly limited, and for example, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, It may be alcoholic beverages and vitamin complexes.
- the food composition may further include additional ingredients, such as flavoring agents or natural carbohydrates, in addition to active ingredients, like conventional food.
- Natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol.
- the sweetener include natural sweeteners such as taumatin and stevia extract; and synthetic sweeteners such as saccharin and aspartame.
- the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol , a carbonation agent used in carbonated beverages, and the like.
- it may contain the pulp for the production of natural fruit juice, fruit juice beverage and vegetable beverage.
- the present invention provides a method for preventing or treating influenza A virus infection disease comprising administering the above-described antiviral composition to a subject.
- the present invention provides a method for treating influenza A virus-infected disease comprising administering the above-described antiviral composition to a subject.
- the subject may be a human and/or a non-human animal, and specifically, a mammal capable of exhibiting beneficial effects by treatment using the drug of the present invention.
- Subjects may include all subjects who have or are at risk of having symptoms of influenza A virus-infected disease (eg, fever, malaise, cough, dyspnea, pneumonia, phlegm, sore throat, flu, cold, etc.) there is.
- influenza A virus is the same as described above, and a detailed description thereof will be omitted.
- An amount effective for preventing or treating an influenza A virus-infected disease means an amount capable of achieving a desired outcome in a subject in need thereof, or an amount capable of providing an objective or subjective benefit to a subject in need of treatment.
- An amount effective to prevent or treat an influenza A virus infection disease may be a single or multiple doses.
- An effective amount for preventing or treating influenza A virus infection disease may be the amount when the drug of the present invention is provided alone, but when provided in combination with one or more other compositions (eg, other respiratory disease treatment agents, etc.) It may be a quantity.
- the present invention provides the use of a pharmaceutical composition comprising the above-described antiviral composition for the prevention or treatment of influenza A virus infection disease.
- the present invention provides the use of a pharmaceutical composition comprising the above-mentioned antiviral composition for the treatment of influenza A virus-infected disease.
- MDCK cells were preserved in Eagle's minimal essential medium (EMEM) containing 5% fetal bovine serum (Gibco, Cergy Pontois, France), 100 U/ml penicillin and 100 ⁇ g/ml streptomycin (Hyclone, Logan, UT, USA).
- EMEM Eagle's minimal essential medium
- HeLa and Vero cells were cultured in DMEM (Dulbecco's Modified Eagle's medium), and A549 cells were cultured in Roswell park Memorial Institute 1640 medium (RPMI 1640 medium; Hyclone) containing the same serum as the MDCK culture medium.
- RPMI 1640 medium Roswell park Memorial Institute 1640 medium; Hyclone
- Influenza strains A/Puerto Rico/8/34 (H1N1/PR8) and A/X-31 (H3N2/X-31) were provided by Professor Kweon (Sungkyunkwan University, Korea).
- the Pandemic H1N1/H275Y NA mutant virus (A/Korea/2785/2009pdm: NCCP 42017; Oseltamivir-resistant) was obtained from the National Pathogen Resources Bank.
- H1N1/H275Y is a variant resulting from H1N1/pdm09. Viruses were propagated in the allantoic sacs of 9-day-old eggs at 37°C for 3 days. Allantoic fluid was harvested and removed using density gradient centrifugation. Viral titers were determined using plaque assay.
- the 3D8 scFv was eluted with 0.1 M acetic acid (pH 3.4). The eluted fractions were neutralized with 0.1 volume of 1 M Tris-HCl (pH 9.0). The concentration of purified 3D8 scFv was determined based on the extinction coefficient at 280 nm. Proteins were analyzed by electrophoresis on a 12% SDS polyacrylamide gel and detected by Coomassie blue staining.
- A549, HeLa, Vero and MDCK cells (2x10 4 ) were cultured in 8-well chamber slides (Nunc Lab-Tek). Cells were treated with 3 ⁇ M 3D8 scFv and incubated at 37° C. with 5% CO 2 for 24 hours. Next, the slides were washed twice with PBS and fixed in methanol at 25° C. for 15 minutes. Samples were permeabilized for 5 minutes using Intracellular Staining Perm wash buffer (BioLegend, San Diego, CA, USA).
- samples were incubated with monoclonal mouse anti-3D8 scFv antibody (1:1000 dilution; AbClon, Seoul, Korea) at 4°C for 24 hours.
- samples were incubated with goat anti-mouse IgG Alexa Fluor 488 secondary antibody (1:1000 dilution; Abcam, Cambridge, MA, USA) for 1 h at 25 °C and slides were incubated with DAPI (Vectashield, Burlingame, CA, USA) was mounted on antifade Mounting Medium. Samples were then visualized using a Zeiss LSM 700 confocal microscope.
- the reaction was terminated by adding 10X loading buffer (Takara, Otsu, Shinga, Japan), and the reaction was analyzed by electrophoresis on a 1% agarose gel and stained with ethidium bromide. As a result of the analysis, it was confirmed that viral RNA was degraded by 3D8 scFv treatment (FIG. 4).
- MDCK cells (2 ⁇ 10 4 ) were cultured in 96-well plates. Cells were treated with 3D8 scFv (1-10 ⁇ M) and incubated at 37° C. with 5% CO 2 for 48 hours. Then, 10 ⁇ l of MTT solution was added and the cells were incubated at 37° C., 5% CO 2 for 4 hours. Formazan crystals formed were dissolved with DMSO and the absorbance of each well was read at 595 nm using an ELISA microplate reader (TECAN, Mannedorf, Switzerland).
- Cytotoxicity was confirmed by treating MDCK cells with different concentrations of 3D8 scFv (0 to 10 ⁇ M). A minimal cytotoxicity of less than 5% was observed at all concentrations, indicating that the toxicity of the 3D8 scFv was kept to a minimum at the concentration at which the experiment was performed ( FIG. 5 ).
- 3D8 scFv pretreatment 3D8 scFv (3, 5, 7 ⁇ M) was added to MDCK cells at 37° C., 5% CO 2 . After 24 hours of treatment, 3D8 scFv-treated cells were independently treated with three influenza virus strains (H1N1/PR8, H3N2/X-31 and H1N1/H275Y) in MEM-free medium at 37°C for 1
- the infection medium was then removed and the cells were cultured in serum-free MEM-free medium (1% BSA) containing tosylphenylalanyl chloromethyl ketone (TPCK)-treated trypsin (1 ⁇ g/ml) at 37°C, 5% CO. Incubated for 48 hours at 2 (top of FIG. 6).
- TPCK tosylphenylalanyl chloromethyl ketone
- H1N1/H275Y-infected cells displayed a drug-resistant phenotype, whereas H1N1/PR8 and H3N2/X-31-infected cells did not. didn't
- the survival rate of the 3D8 scFv untreated group (0 ⁇ M) was about 62.7%, whereas the survival rate of the group post-treated with 5 ⁇ M 3D8 scFv was 84.4% (H3N2/X-31 in FIG. 7 ). Post)).
- the survival rate of the 3D8 scFv untreated group (0 ⁇ M) was about 58.4%, whereas the survival rate of all 3D8 scFv-treated groups was about 77.4% (H1N1/H275Y (Post) in FIG. 7 ).
- Treatment of 3D8 scFv before or after viral infection in vitro increased the viability of virus-infected cells by 20%.
- MEM-free medium 1% BSA
- TPCK tosyl phenylalanyl chloromethyl ketone
- the group pretreated with 3D8 scFv decreased viral HA and NP RNA expression by more than 40% compared to the group untreated with 3D8 scFv (H3N2/X-31 (Pre) in FIG. 9), In the group treated with 3D8 scFv, HA and NP RNA expression of the virus was reduced by 40% or more compared to the group not treated with 3D8 scFv (H3N2/X-31 (Post) in FIG. 9 ).
- the group pretreated with 3D8 scFv showed a 35% or more decrease in viral HA and NP RNA expression compared to the group untreated with 3D8 scFv (H1N1/H275Y(Pre) in FIG. 10) and 3D8 scFv
- the post-treatment group also showed a decrease in viral HA and NP RNA expression by 40% or more compared to the 3D8 scFv untreated group (H1N1/H275Y(Post) in FIG. 10).
- MDCK cells (2 ⁇ 10 4 ) were cultured in 8-well chamber slides. 3D8 scFv treatment and virus infection (H1N1/PR8 and H1N1/H275Y) were performed in the same manner as described in (1) above (upper side of FIG. 8). The slides were washed twice with PBS and fixed for 15 minutes using methanol cooled at 25°C. The sample was permeabilized with Intracellular Staining Perm wash buffer for 5 minutes. After blocking with PBST containing 1% BSA for 1 h, cells were incubated with monoclonal mouse anti-3D8 scFv antibody or polyclonal rabbit anti-HA antibody (1:1000 dilution, Invitrogen) at 4 °C for 24 h. did.
- the cells were then incubated with goat anti-mouse IgG Alexa Fluor 488 secondary antibody or goat anti-rabbit IgG TRITC secondary antibody (1:1000 dilution, Abcam) at 25° C. for 1 hour, respectively. Slides were mounted using anti-fade mounting medium containing DAPI and cells were visualized using a Zeiss LSM 700 confocal microscope.
- the 3D8 scFv pre-treated group of H1N1/H275Y-infected cells had a lower detection signal of viral HA protein than the 3D8 scFv untreated group (H1N1/H275Y in FIG. 11 ).
- the 3D8 scFv post-treatment group had a lower viral HA protein signal than the 3D8 scFv untreated group ( FIG. 12 ).
- mice were housed under standard laboratory conditions. These mice were divided into 5 groups of 8-10 mice.
- SPF pathogen-free
- mice PBS treatment prior to virus infection in each group of mice; PBS treatment after viral infection; 3D8 scFv treatment prior to viral infection; 3D8 scFv treatment after viral infection; And Oseltamivir phosphate (Sigma-Aldrich, ST. Louis, MO, USA) was orally administered for 5 days after viral infection.
- Mice in each group were intranasally infected with 50 ⁇ l lethal dose of 50% H1N1/H275Y virus (5 ⁇ 10 4 PFU). Mice were infected with H1N1/H275Y and monitored daily for clinical signs (weight change, cough, slouched back, coarse hair, flocking (fever), abnormal secretions, survival, etc.) until day 11 (Fig. 13).
- mice did not show abnormal clinical signs, and histopathologically, abnormal changes in the lung parenchyma and its stroma did not appear ( FIG. 14 ).
- 3D8 scFv was found to be localized to the epithelial lining of bronchioles and alveoli for 48 hours after administration ( FIG. 15 ).
- the average body weight of the PBS pretreatment group was 21.1 g after infection 0 (0 dpi), and decreased by 27% to 15.5 g after 11 infection (11 dpi).
- the average body weight of the 3D8 scFv pretreatment group was 22.2 g at 0 dpi, and decreased by about 18% from 7 dpi to 18.2 g.
- the average body weight decreased by 21.8 g at 0 dpi and 30% at 7 dpi, and rebounded at 11 dpi.
- the average body weight was 20.8 g at 0 dpi, but no mice survived at 8 dpi.
- the average body weight of the 3D8 scFv post-treatment group was 23 g at 0 dpi and decreased by about 30% from 10 dpi to 16 g, but the average body weight recovered thereafter ( FIG. 17 ).
- Each lung lobe was assigned a number reflecting the approximate percentage of total lung volume. The total score for all lobes formed an estimate of the percentage of total lungs with grossly visible pneumonia.
- lung tissue was fixed in 10% neutral buffered formalin. After fixation, the tissue was dehydrated through a series of alcohol solutions and xylene, and embedded in paraffin wax. Sections (5 ⁇ m) were prepared from each tissue and hematoxylin and eosin (HE) staining was performed.
- HE hematoxylin and eosin
- the total lung lesion score was significantly lower in the 3D8 scFv pre-treatment group than in the 3D8 scFv post-treatment group (P ⁇ 0.05).
- the oseltamivir-treated group had a significantly lower total lung lesion score than the PBS-treated group (P ⁇ 0.05) (bottom of FIG. 18).
- the microscopic lesion was characterized by a thickened alveolar septum with increased numbers of interstitial macrophages and lymphocytes in the PBS and oseltamivir treated groups.
- Lungs of 3D8 scFv pre-treatment and WT group were normal (top of FIG. 19 ).
- the 3D8 scFv pre-treatment group had significantly lower microscopic lesion scores than the other groups (P ⁇ 0.01)
- the 3D8 scFv post-treatment group had significantly lower microscopic lesion scores than the PBS and oseltamivir-treated groups (P ⁇ 0.05).
- There was no significant difference in the microscopic lung lesion score between the PBS-treated group and the oseltamivir-treated group bottom of FIG. 19).
- RNA and interferon levels were measured in the lungs of mice.
- Total RNA was extracted from lysed mouse lung tissue (5 dpi) samples using TRI reagent according to the manufacturer's instructions. RNA concentration was determined using a spectrophotometer.
- cDNA was synthesized using CellScript All-in-One 5x First Strand cDNA Synthesis Master Mix according to the manufacturer's protocol. The genes (HA, NP and IFN- ⁇ ) were amplified with the primers in Table 3 using qRT-PCR as previously described. GAPDH was amplified as an internal control.
- virus titers were confirmed in the lungs of influenza A virus-infected mice.
- Mouse lung tissue was homogenized in 1 ml of MEM-free medium using TissueRuptor (Qiagen, Chadstone, Victoria, Australia). A homogenate was obtained by centrifugation at 6,000 ⁇ g for 5 min at 4°C.
- Confluent MDCK cells were cultured in 12-well plates. After infecting the tissue supernatant (1:1000 dilution) in MEM-free medium at 37° C. for 1 hour, the infection medium was removed. The medium was replaced with 1 ⁇ Dulbecco's modified eagle medium containing TPCK-treated trypsin (1 ⁇ g/ml) and 1% agarose.
- the viral titer of the lungs was reduced by about 70% in the 3D8 scFv pretreatment group compared to the PBS pretreatment group ( FIG. 21 ).
- the viral titer of the lungs was reduced by about 60% in the 3D8 scFv post-treatment group compared to the PBS post-treatment group ( FIG. 21 ).
- tissue sections After deparaffinizing and rehydrating the tissue sections, antigen recovery was performed at 95° C. for 20 minutes using citrate buffer. Slides were washed with TBST (TBS, 0.025% Triton X-100) and blocked with 10% fetal bovine serum + 1% BSA solution (in TBST) for 2 hours. Tissue sections were incubated with polyclonal rabbit anti-HA antibody (1:750 dilution) overnight at 4°C. The tissue slides were then each incubated with goat anti-rabbit IgG TRITC secondary antibody (1:1000 dilution) at 25° C. for 1 hour.
- Anti-fade mounting medium containing DAPI was put on tissue section slides, a cover glass was put on, and cells were visualized using an LSM 700 Zeiss confocal microscope.
- the signal of viral HA was reduced in the alveolar epithelial cell inner layer (left in Fig. 22), and the number of distinct positive signals was significantly lower in the 3D8 scFv pre-treated group compared to the oseltamivir-treated group (P ⁇ 0.05) (Fig. 22). right).
- 3D8 scFv not only exhibits a prophylactic effect of protecting the host from viral infection, but also exhibits a therapeutic effect by alleviating excessive inflammation and potential additional etiology after viral infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
구분 | 아미노산 서열 | 서열번호 |
VH CDR1 | GYTFTSYVMH | 서열번호 1 |
VH CDR2 | INPYNDG | 서열번호 2 |
VH CDR3 | GAYKRGYAMDY | 서열번호 3 |
VL CDR1 | KSSQSLFNSRTRKNYLA | 서열번호 4 |
VL CDR2 | WASTRES | 서열번호 5 |
VL CDR3 | KQSYYHMYT | 서열번호 6 |
VH | EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGAYKRGYAMDYWGQGTSVTVSSR | 서열번호 7 |
VL | DLVMSQSPSSLAVSAGEKVTMSCKSSQSLFNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYYHMYTFGSGTKLEIK | 서열번호 8 |
3D8 scFv | EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGAYKRGYAMDYWGQGTSVTVSSRGGGGSGGGGSGGGGSDLVMSQSPSSLAVSAGEKVTMSCKSSQSLFNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYYHMYTFGSGTKLEIK | 서열번호 9 |
3D8 scFv 유전자 서열 | GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTAGCTATGTTATGCACTGGGTGAAGCAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATATTAATCCTTACAATGATGGTACTAAGTACAATGAGAAGTTCAAAGGCAAGGCCACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTCTATTACTGTGCAAGAGGGGCCTATAAAAGGGGATATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCTAGAGGTGGGGGCGGTTCGGGTGGCGGGGGCTCGGGCGGGGGTGGCTCAGATCTTGTGATGTCACAGTCTCCATCCTCCCTGGCTGTGTCAGCAGGAGAGAAGGTCACTATGAGCTGCAAATCCAGTCAGAGTCTGTTCAACAGTAGAACCCGAAAGAACTACTTGGCTTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTGATCTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGCAAGCAATCTTATTATCACATGTATACGTTCGGATCGGGGACCAAGCTGGAAATAAAA | 서열번호 10 |
유전자 | Forward (5'->3') | Reverse (5'->3') | Accession No. |
Hemagglutinin (HA) | GCTACCATGCGAACAATTCAAC (서열번호 11) | CTGCACTGCAAAGATCCATTAG (서열번호 12) | NC_002017.1 |
Neuramindase (NA) | CCATTGGATCAATCTGTCTGG (서열번호 13) | TGTCAATGGTGAATGGCAACTC (서열번호 14) | NC_002018.1 |
Nucleoprotein (NP) | ACTGATGGAGAACGCCAGAAT (서열번호 15) | ATGTCAAAGGAAGGCACGATC (서열번호 16) | NC_002019.1 |
유전자 | Forward(5'->3') | Reverse(5'->3') | Accession No. |
GAPDH (MDCK Cell Line) | AAC ATC ATC CCT GCT TCC ACT (서열번호 17) | GGC AGG TCA GAT CCA CAA C (서열번호 18) | NM_001003142.2 |
GAPDH (Mouse) | GGC ATT GCT CTC AAT GAC AA (서열번호 19) | TGT GAG GGA GAT GCT CAG TG (서열번호 20) | NC_000072.7 |
Hemagglutinin (A/PuertoRico/8/1934 (H1N1)) | AGT GCC CAA AAT ACG TCAG G (서열번호 21) | CAG TCC ATC CCC CTT CAA TA (서열번호 22) | NC_002017.1 |
Hemagglutinin (A/X-31 (H3N2)) | GAA AAT GGT TGG GAG GGA ATG (서열번호 23) | GAT GGC TGC TTG AGT GCT TTT (서열번호 24) | DQ874876.1 |
Hemagglutinin (A/California/07/2009(H1N1)) | GGA ACG TGT TAC CCA GGA G (서열번호 25) | GCT GCC GTT ACA CCT TTG TT (서열번호 26) | NC_026433.1 |
Nucleoprotein (A/PuertoRico/8/1934 (H1N1)) | ACC AAT CAA CAG AGG GCA TCT (서열번호 27) | TGA TTT CGG TCC TCA TGT CAG (서열번호 28) | NC_002019.1 |
Nucleoprotein (A/X-31 (H3N2)) | AAA ATC ATG GCG TCT CAA GGC (서열번호 29) | CGG TGC ACA TTT GGA TGT AGA (서열번호 30) | AB036779.1 |
Nucleoprotein (A/California/07/2009(H1N1)) | CCA GAT CAG TGT GCA GCC TA (서열번호 31) | GGC TTT GCA CTT TCC ATC ATT C (서열번호 32) | NC_026436.1 |
Interferon beta (Mouse) | TTA CAC TCG CTT TGC CAT CCA A (서열번호 33) | TCC CAC GTC AAT CTT TCC TCT T (서열번호 34) | NC_000070.6 |
Claims (12)
- 서열번호 1로 표시되는 중쇄 CDR1(VH CDR1), 서열번호 2로 표시되는 VH CDR2, 및 서열번호 3으로 표시되는 VH CDR3, 서열번호 4로 표시되는 경쇄 CDR1(VL CDR1), 서열번호 5로 표시되는 VL CDR2 및 서열번호 6으로 표시되는 VL CDR3을 포함하는 항체 또는 이의 단편을 포함하는 인플루엔자 A 바이러스에 대한 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 항체 또는 이의 단편은 서열번호 7의 아미노산 서열을 포함하는 중쇄가변영역을 포함하는 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 항체 또는 이의 단편은 서열번호 8의 아미노산 서열을 포함하는 경쇄가변영역을 포함하는 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 단편은 서열번호 9의 아미노산 서열을 포함하는 scFv인 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 인플루엔자 A 바이러스는 인플루엔자 A 바이러스 H1 서브타입, 인플루엔자 A 바이러스 H2 서브타입, 인플루엔자 A 바이러스 H5 서브타입 및 인플루엔자 A 바이러스 H6 서브타입, 인플루엔자 A 바이러스 H3 서브타입, 인플루엔자 A 바이러스 H4 서브타입, 인플루엔자 A 바이러스 H14 서브타입 및 이들의 변이체로 이루어진 군에서 선택된 적어도 하나인 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 인플루엔자 A 바이러스는 인플루엔자 A 바이러스 N1 서브타입, 인플루엔자 A 바이러스 N2 서브타입 및 이들의 변이체로 이루어진 군에서 선택된 적어도 하나인 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 인플루엔자 A 바이러스는 H1N1 서브타입, H3N2 서브타입 및 이들의 변이체 중 적어도 하나인 항바이러스용 조성물.
- 청구항 1에 있어서, 상기 인플루엔자 A 바이러스는 오셀타미비르 저항성 인플루엔자 A 바이러스인 항바이러스용 조성물.
- 청구항 1 내지 8 중 어느 한 항의 조성물을 포함하는 인플루엔자 A 바이러스 감염 질환의 예방 또는 치료용 약학 조성물.
- 청구항 9에 있어서, 인플루엔자 A 바이러스 감염 질환의 치료용 약학 조성물.
- 청구항 1 내지 8 중 어느 한 항의 조성물을 포함하는 인플루엔자 A 바이러스 감염 질환의 예방 또는 개선용 식품 조성물.
- 청구항 11에 있어서, 인플루엔자 A 바이러스 감염 질환의 개선용 식품 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180052536.6A CN116367856A (zh) | 2020-09-08 | 2021-09-08 | 针对甲型流感病毒的抗病毒组合物 |
EP21867109.7A EP4212548A4 (en) | 2020-09-08 | 2021-09-08 | ANTIVIRAL COMPOSITION AGAINST INFLUENZA A VIRUS |
JP2023515629A JP2023540373A (ja) | 2020-09-08 | 2021-09-08 | インフルエンザaウイルスに対する抗ウイルス用組成物 |
US18/021,989 US20240018218A1 (en) | 2020-09-08 | 2021-09-08 | Antiviral composition against influenza a virus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063075456P | 2020-09-08 | 2020-09-08 | |
US63/075,456 | 2020-09-08 | ||
KR1020210119473A KR20220033038A (ko) | 2020-09-08 | 2021-09-08 | 인플루엔자 a 바이러스에 대한 항바이러스용 조성물 |
KR10-2021-0119473 | 2021-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022055243A1 true WO2022055243A1 (ko) | 2022-03-17 |
Family
ID=80629726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/012191 WO2022055243A1 (ko) | 2020-09-08 | 2021-09-08 | 인플루엔자 a 바이러스에 대한 항바이러스용 조성물 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240018218A1 (ko) |
JP (1) | JP2023540373A (ko) |
WO (1) | WO2022055243A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR100E (fr) | 1901-10-14 | 1902-10-24 | Legrand Sa | Un appareil dénommé "marquette manille" |
KR20130140050A (ko) * | 2010-11-02 | 2013-12-23 | 헥토 마뉴엘 제페다 로페즈 | A/h1n1 범유행 인플루엔자 바이러스에 대한 신규한 백신 |
KR20140012098A (ko) * | 2011-02-14 | 2014-01-29 | 테라클론 사이언시스, 아이엔씨. | 인플루엔자의 치료 및 진단을 위한 조성물 및 방법 |
US20150010566A1 (en) * | 2011-12-02 | 2015-01-08 | Hergen Spits | Influenza a virus specific antibodies |
-
2021
- 2021-09-08 WO PCT/KR2021/012191 patent/WO2022055243A1/ko active Application Filing
- 2021-09-08 JP JP2023515629A patent/JP2023540373A/ja active Pending
- 2021-09-08 US US18/021,989 patent/US20240018218A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR100E (fr) | 1901-10-14 | 1902-10-24 | Legrand Sa | Un appareil dénommé "marquette manille" |
KR20130140050A (ko) * | 2010-11-02 | 2013-12-23 | 헥토 마뉴엘 제페다 로페즈 | A/h1n1 범유행 인플루엔자 바이러스에 대한 신규한 백신 |
KR20140012098A (ko) * | 2011-02-14 | 2014-01-29 | 테라클론 사이언시스, 아이엔씨. | 인플루엔자의 치료 및 진단을 위한 조성물 및 방법 |
US20150010566A1 (en) * | 2011-12-02 | 2015-01-08 | Hergen Spits | Influenza a virus specific antibodies |
Non-Patent Citations (3)
Title |
---|
CHO SEUNGCHAN, YOUN HA-NA, HOANG PHUONG, CHO SUNGRAE, KIM KEE-EUN, KIL EUI-JOON, LEE GUNSUP, CHO MUN-JU, HONG JUHYUN, BYUN SUNG-JU: "Preventive Activity against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice", VIRUSES, vol. 7, no. 9, 21 September 2015 (2015-09-21), pages 5133 - 5144, XP055910655, DOI: 10.3390/v7092863 * |
DATABASE PROTEIN 12 March 2015 (2015-03-12), ANONYMOUS : "3D8 single-chain variable fragment, partial [synthetic construct]", XP055910657, retrieved from NCBI Database accession no. AIN44217 * |
LEE YONGJUN, KIM DONGJUN, KIM TAEHYUN, OH YEONSU, KIM WON-KEUN, LEE SUKCHAN: "Antiviral effect of a nucleic acid hydrolyzing scFv against oseltamivir resistant influenza A virus", BIORXIV, 22 February 2021 (2021-02-22), XP055910652, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.02.19.432068v1.full.pdf> DOI: 10.1101/2021.02.19.432068 * |
Also Published As
Publication number | Publication date |
---|---|
US20240018218A1 (en) | 2024-01-18 |
JP2023540373A (ja) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018034522A1 (ko) | 코어와 그의 표면에 결합된 시알산, 시알릴락토스 또는 이들의 유도체를 포함하는 결합체 및 그의 용도 | |
WO2021235616A1 (ko) | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 | |
WO2022050516A1 (ko) | 담팔수 추출물을 유효성분으로 포함하는 코로나 바이러스 치료제 | |
WO2017039365A1 (ko) | D-싸이코스를 이용한 지질 흡수 억제 및/또는 배출 촉진 방법 | |
WO2012023660A1 (ko) | 크레이스토카릭스 오페르쿠라투스로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제 | |
WO2022055243A1 (ko) | 인플루엔자 a 바이러스에 대한 항바이러스용 조성물 | |
WO2020032365A1 (ko) | 진세노사이드 화합물을 함유하는 인플라마좀 매개 염증성 질환의 예방 또는 치료용 조성물 | |
WO2011099812A2 (ko) | 감초 추출물을 포함하는 로타바이러스 감염의 예방 또는 치료용 조성물 | |
WO2022124800A1 (ko) | 푸코실락토스를 유효성분으로 함유하는 항바이러스 조성물 | |
WO2022225330A1 (ko) | 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드 | |
WO2022031151A1 (ko) | 고사리 추출물 또는 이의 분획물을 포함하는 항바이러스용 조성물 | |
EP4212548A1 (en) | Antiviral composition against influenza a virus | |
EP4194466A1 (en) | Antiviral composition against coronavirus | |
WO2022071576A1 (ja) | 新型コロナウイルス感染症の予防又は治療のための抗ウイルス剤 | |
WO2021172755A1 (ko) | 매실 추출물을 유효성분으로 포함하는 인플루엔자 바이러스 감염 예방 또는 치료용 약학적 조성물 | |
WO2014051359A1 (ko) | 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물 | |
WO2019022357A1 (ko) | 중동호흡기 증후군의 예방 또는 치료용 약학조성물 | |
WO2022031137A1 (ko) | 코로나바이러스에 대한 항바이러스용 조성물 | |
WO2015108372A1 (ko) | 오스모틴을 포함하는 흥분독성 또는 시냅스 기능 장애에 의한 신경 질환의 예방 또는 치료용 조성물, 및 이를 이용한 신경 질환의 예방 또는 치료 방법 | |
WO2016013793A1 (ko) | 감마 허피스바이러스 감염의 개선 및 치료에 사용하기 위한 아까시나무 추출물, 아카세틴 및 아피제닌의 용도 | |
WO2021225344A1 (ko) | 코로나 바이러스 억제용 펩타이드 및 그 용도 | |
WO2023171998A1 (ko) | 동맥경화를 포함하는 노화성 혈관질환 치료 또는 예방용 조성물로서의 사이코사포닌 c | |
WO2023172034A1 (ko) | 더덕속, 참취속 및/또는 원지속 식물 추출물을 포함하는 외막형 바이러스의 예방 및 치료용 약학 조성물 | |
WO2022215827A1 (ko) | Sars-cov-2 3cl 프로테아제와 rdrp활성을 억제하는 지유 추출 조성물 | |
WO2022270760A1 (ko) | 커큐민 유도체와 tgf-β 수용체 억제제의 병용투여를 통한 비알코올성 지방간염 치료 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21867109 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18021989 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2023515629 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021867109 Country of ref document: EP Effective date: 20230411 |